Is the neutrophil-to-lymphocyte ratio a useful prognostic indicator in melanoma patients?
Joshua T CohenThomas J MinerMichael P VezeridisPublished in: Melanoma management (2020)
The neutrophil-to-lymphocyte ratio (NLR) is gaining traction as a biomarker with utility in a variety of malignancies including melanoma. Intact lymphocyte function is necessary for tumor surveillance and destruction, and neutrophils play a role in suppressing lymphocyte proliferation and in the induction of lymphocyte apoptosis. Early research in melanoma indicates that in high-risk localized melanoma, a high NLR is correlated with worse overall and disease-free survival. Similarly, in metastatic melanoma treated with both metastasectomy and immunotherapies, an elevated NLR is predictive of shortened overall survival and progression-free survival. Future studies incorporating NLR into more traditional melanoma prognostic markers while employing more granular outcomes, are needed to realize the full potential of NLR.
Keyphrases
- free survival
- skin cancer
- end stage renal disease
- peripheral blood
- newly diagnosed
- signaling pathway
- ejection fraction
- chronic kidney disease
- public health
- oxidative stress
- type diabetes
- basal cell carcinoma
- cell death
- cell proliferation
- prognostic factors
- metabolic syndrome
- climate change
- cell cycle arrest
- skeletal muscle
- pi k akt